News

Uncoordinated price cuts across the EU are contributing to medicine shortages and driving manufacturers towards more ...
The amended product information will provide more specific detail on encephalitis as a known adverse reaction to ...
The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s ...
In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally ...
People of a certain age may remember Merthiolate and Mercurochrome in the household medicine chest. Whenever someone skinned ...
New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE ...
Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...
JHU's Neurofibromatosis Therapeutic Acceleration Program celebrated the 10th anniversary of its Francis S. Collins Scholars ...
Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug ...
July, 11 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating ...
The agency’s Executive Steering Group on Shortages and Safety of Medicinal Products has issued recommendations to address ...
Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.